Drugs in the Pipeline
Phase 2/3 Study Data Announced for Vectibix in Colorectal Cancer
Amgen announced new data from its PEAK and PRIME studies that support Vectibix (panitumumab), in combination with FOLFOX, as first-line therapy in patients with wild-type RAS metastatic colorectal cancer (mCRC)